about
The role of the clinical research coordinator--data manager--in oncology clinical trialsMicroRNAs: promising new antiangiogenic targets in cancerCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trialScreening for epidermal growth factor receptor mutations in lung cancerCost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer.Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.Gene panel sequencing improves the diagnostic work-up of patients with idiopathic erythrocytosis and identifies new mutations.The quest for epigenetic regulation underlying unisexual flower development in Cucumis melo.Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancThe small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosisControversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.Targeted therapy in combination with gemcitabine in non-small cell lung cancer.Influence of genetic markers on survival in non-small cell lung cancer.Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung CancerTargeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.Pharmacogenomics and gemcitabine.Anorexia-Cachexia syndrome in cancer: implications of the ubiquitin-proteasome pathway.The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents.Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy.Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer.Can the Spanish care system assume the new costs of medications against cancer?Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.Importance of quality of life in patients with non-small-cell lung cancer.Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.Update on biomarkers for the detection of lung cancer.The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer.The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer.
P50
Q24797913-E23A2BC6-CE04-472C-81D2-494C1E7A5DE1Q27027998-7E375D56-8D41-4BE2-B66C-947F527B967CQ28077340-CFB4F866-162F-4EE3-BE3F-81F22DF6C2A5Q28377003-A360DC56-CD0A-4131-9821-0BF969C7FFA6Q29619696-B66697CA-5E2B-4ECE-984D-22883FEB8F6AQ30977332-72158DA4-0E6D-46AD-ADD5-F2B0165D4E11Q31108477-354CB454-0893-42C1-9C15-ECD718479EDAQ31960257-A0C2F8F4-D1FD-4D5C-91F4-468C81CCFE7CQ33214386-E345F69F-74D3-46F9-9B33-37809A44555BQ33331466-8FFB8223-66AA-4382-8532-DE891E2D6EBDQ33342699-EA72D149-8394-45E1-91C6-D363CA264AF3Q33349736-E9AE4D42-34DE-42D8-B1FF-6833233C0B00Q33357840-315110BD-19BE-47CE-A855-DBADD450593EQ33364765-DD7CDC18-3DC4-4B5D-8889-9BC2F1AFE5B3Q33521596-711B58EC-8A43-4C61-AE89-80134B7BF8A8Q33573521-7EC71A5C-4997-4399-9105-8DF1DAB5FD3DQ33768025-3813CE6D-1104-4230-8952-539DE86C607BQ34467915-F82AF908-6551-41DC-B5A9-97064D048BC1Q34534314-A76DD0B1-0429-40CF-BBB8-60C97E431B84Q34745747-8FBC8D7A-D768-4713-9F51-4FD98AA0627FQ35180823-A0AD83F4-E1A8-44F7-9A64-308600E5FBE6Q35199311-CA8D561B-5F1F-431A-9467-D61E54FFF541Q35605492-3EBD19E0-7A30-462F-B5B8-3D199C3632EEQ35826391-929EEB8B-BD21-4CBA-84F8-EC60D5D2BE8BQ36132165-E8C9B8B0-80AE-44EA-BED0-0886B4CE3498Q36279825-F73665EE-E7FA-41E2-9B68-9706860CA40BQ36345226-3A68BFA8-2B35-4E61-B0C8-BDF7D43B7C4CQ36522699-951D8483-75C5-4254-9023-97FE3C7392F7Q36526950-490587B2-ABB7-4FF9-AB6A-E8FAA9880210Q36724616-1127D812-F443-4AEA-804E-599ACF8B8AF5Q36778247-14BEE6DE-23EB-44F7-B4C9-7F0430E1B3C6Q36846839-CEFFE7D3-4851-46AF-B0DA-CEA398662521Q37022332-50742914-BACB-4D1E-8EEE-0AC177951EEEQ37079449-632832C8-BEF5-409E-AE24-577EAF6B401EQ37180356-1B1F6568-46B9-4C53-85BC-CB1EA68A442DQ37442289-3B4E20DE-FC05-45C5-8831-01F6FF68F5D6Q37619675-61C20C4A-843E-40D5-8E02-C9D75F2C0466Q37645219-769ADD50-EF97-437D-9B65-45C7C38466DCQ37812262-AB9B8E56-F94C-48EC-AA71-DFB64A54C42AQ37822654-1F704E84-CACD-4D8B-9D4F-4C89193104D5
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Carlos Camps
@ast
Carlos Camps
@en
Carlos Camps
@es
Carlos Camps
@nl
Carlos Camps
@sl
type
label
Carlos Camps
@ast
Carlos Camps
@en
Carlos Camps
@es
Carlos Camps
@nl
Carlos Camps
@sl
prefLabel
Carlos Camps
@ast
Carlos Camps
@en
Carlos Camps
@es
Carlos Camps
@nl
Carlos Camps
@sl
P1053
L-3073-2017
P106
P1153
35407295500
P21
P31
P3829
P496
0000-0002-0648-5403